Brief: Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025
14/06/2025 15:50
June 14 (Reuters) - Celldex Therapeutics Inc CLDX.O: CELLDEX PRESENTS DATA DEMONSTRATING PROFOUND LONG TERM IMPROVEMENT IN ANGIOEDEMA IN BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC SPONTANEOUS URTICARIA AT EAACI 2025 Source text: ID:nGNX1jHGbV Further company coverage: CLDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials